IL1B as A Potential Drug Target for Inflammatory Disorders (G3553)

Target Name: IL1B

NCBI ID: G3553

IL1B

IL1B as A Potential Drug Target for Inflammatory Disorders

Interleukin 1 beta (IL-1B), a cytokine that plays a crucial role in the regulation of immune and inflammatory responses, has long been identified as a promising drug target for the treatment of various diseases. IL-1B has been shown to contribute to the development and progression of a wide range of inflammatory disorders, including autoimmune diseases, chronic obstructive pulmonary disease (COPD), and heart failure. In this article, we will explore the biology and pathology of IL-1B and its role as a potential drug target, as well as the current research on its potential therapeutic applications.

The cytokine IL-1B was first identified in the 1970s as a key mediator of inflammation. It is a member of the interleukin family, which includes a variety of cytokines that play important roles in the regulation of immune responses and inflammatory processes. IL-1B is produced by monocytes and macrophages in response to the presence of pathogens or other stimuli, and it travels through the bloodstream to sites of inflammation throughout the body.

The primary function of IL-1B is to regulate the production and activation of other immune cells, such as T cells, B cells, and natural killer cells. It does this by participating in the signaling cascade that activates these cells and controls their proliferation, differentiation, and function. One of the well-documented signaling pathways involving IL-1B is the production of pro-inflammatory cytokines, such as TNF-伪, IL-2, and IL-18. These cytokines contribute to the inflammatory response and tissue damage that occurs in response to an infection or injury.

In addition to its role in immune regulation, IL-1B has also been shown to play a key role in the regulation of cellular processes that are critical for tissue function and survival. It has been shown to promote the production and distribution of extracellular matrix (ECM) components, such as collagen and hyaluronic acid, which are involved in the formation and maintenance of connective tissue. It also contributes to the regulation of cell adhesion and migration, as well as the production of adipoketone, a potent regulator of energy metabolism.

The pathology of IL-1B is well established, and it is involved in the development and progression of a wide range of inflammatory and autoimmune disorders. It is a key player in the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. It has also been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality worldwide.

IL-1B has also been shown to contribute to the development and progression of a variety of other inflammatory disorders, including heart failure, neuroinflammatory diseases, and cancer. For example, studies have shown that IL-1B is involved in the pathogenesis of heart failure, and that inhibition of its activity may be a promising therapeutic approach for this disease.

The potential therapeutic applications of IL-1B are vast and varied. In addition to its role in the treatment of autoimmune and inflammatory disorders, it is also being targeted for its potential anti-inflammatory and anti-cancer effects. One of the most promising approaches for the use of IL-1B is the use of small molecules that can inhibit its activity, such as those that are currently being developed as potential therapeutic agents.

In conclusion, IL-1B is a well-established player in the regulation of immune and inflammatory responses, and it has a long history of being identified as a potential drug target for the treatment of a wide range of disorders. The biological and pathological functions of IL-1B are well understood, and its potential therapeutic applications are vast and varied. Further research is needed to fully understand the mechanisms of its action and to develop safe and effective therapeutic approaches

Protein Name: Interleukin 1 Beta

Functions: Potent pro-inflammatory cytokine (PubMed:3920526, PubMed:10653850, PubMed:12794819, PubMed:28331908). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908)

The "IL1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets